

FOURTH QUARTER 2011

RTI | BIOLOGICS®

A leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI AT A GLANCE

- » Traded on Nasdaq under RTIX
- » Headquartered in Alachua, Fla. with offices in Madison, Wisc. and Dallas, Texas and a facility in Neunkirchen, Germany
- » Approximately 690 global employees
- » Named to the Russell 2000® Index
- » Named to Florida Trend Top 250 Public Companies
- » Accredited by the American Association of Tissue Banks
- » Received 2009 Governor's Business Award for Expansion
- » Named 2009 Business of the Year – Expansion Category by the Gainesville Chamber of Commerce



RTI's innovations continuously raise the bar of science and safety for biologics—from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps. Two such processes—the BioCleanse® and Tutoplast® Tissue Sterilization Processes—sterilize tissue, are clinically successful and are scientifically proven to address donor-to-recipient disease transmission risk while preserving tissue strength and biocompatibility. These processes have a proven record of millions of implants distributed with zero incidence of allograft associated infection.

RTI's worldwide corporate headquarters are located in Alachua, Fla., with an international facility in Germany. The company is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed.

MEDICAL MEETINGS/ INVESTOR MEETINGS

February 7

RTI Biologics Analyst Reception
(San Francisco, Calif.)

February 7


Canaccord Genuity Musculoskeletal Conference
(San Francisco, Calif.)

February 8 – 11

American Academy of Orthopaedic Surgeons
Booth #4137, Hall E
(San Francisco, Calif.)

February 29 – March 2

Lazard Capital Markets Medical Technology
Snowbird Conference
(Snowbird, Utah)




REVENUES (in thousands)

12 months ended December 31, 2011

■ Sports Medicine	\$48,122
■ Spinal Constructs	\$39,722
■ Surgical Specialties	\$30,328
■ BGS/General Orthopedic	\$26,291
■ Dental	\$18,392
■ Other non-tissue	\$6,461
Total	\$169,316

International:
\$21,001



Forward-Looking Statement

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this document are subject to certain risks and uncertainties. Actual results could differ materially from current expectations.

The information contained herein is not a prospectus and does not constitute an offer to sell nor a solicitation of an offer to buy any security.

Market Data as of 12/31/11

NASDAQ: RTIX

Price: \$4.44

52-week range: \$2.44 – \$4.70

Shares Outstanding: 55.6MM

Market Cap: Approx. \$247M

Analyst Coverage

The Benchmark Company – Raymond Myers

Canaccord Genuity – William Plavonic

Craig Hallum – Matt Hewitt

Raymond James & Associates – Jayson Bedford

Roth Capital – Matt Dolan

Stephens Inc. – Chris Cooley

FULL-YEAR & QUARTERLY GUIDANCE

- Full year revenues for 2012 are expected to be between \$174 million to \$176 million.
- Full year net income per fully diluted share expected to be in the range of \$0.15 to \$0.17, based on 55.8 million shares outstanding.
- For the first quarter of 2012, the company expects revenues to be between \$41 million to \$42 million, and net income per fully diluted share to be approximately \$0.03.

BUSINESS MODEL


Recovery: In conjunction with recovery agencies, support tissue donation through donation education and donor family services.

Processing: Demand-focused processing model allows for increased efficiency and effectiveness. Proprietary, validated tissue sterilization processes, including the BioCleanse® and Tutoplast® Tissue Sterilization Processes, lend a competitive advantage as clinically proven sterilization processes that will not negatively affect the tissue.

Distribution: Implants are delivered to surgeons through an optimized distribution model of direct distributors and strategic distribution relationships.

REVENUES BY YEAR (in millions)

*2008 Includes revenues for the former Tutogen Medical, Inc. from 2/28/08 to 12/31/08.



STOCK PRICE PERFORMANCE

6 months ended December 31, 2011



Recognition and Indexes

- 2009 Governor's Business Expansion Award
- World Economic Forum 2004 Technology Pioneer
- Florida Trend Top 250 Public Companies
- Russell 2000® Index
- Russell 3000® Index

Distributors

Aesculap Implant Systems, Inc.: spinal implants

Alphatec Spine, Inc.: spinal implants

Coloplast Corporation: urology implants

Davol, Inc: hernia repair implants, breast reconstruction implants

ENTrigue Surgical, Inc.: ear, nose and throat implants

Exactech, Inc: bone graft substitutes

IOP: ophthalmology implants

Integra: spinal implants

Medtronic Spine: spinal implants

Orthofix Medical: spinal implants

Stryker Corporation: spinal implants


Wright Medical Group: xenograft implants for orthopedics

Zimmer Holdings, Inc: bone graft substitutes, dental and spinal implants

BENEFITS AND APPLICATIONS OF DONATED HUMAN TISSUE

Sport Medicine: Tears to the Anterior Cruciate Ligament (ACL) are the most common sports related injury. In many cases, the surgeon must replace the ACL using a Bone-Tendon-Bone (BTB) allograft. The advantage of using a BTB allograft is the lack of a second surgery site and less time in the operating room.

Shaped and sized to strict specifications in carefully controlled clean rooms, then processed to ensure safety and efficacy, RTI offers surgeons a solution for tendon and bone graft needs with convenience and unmatched safety.



Spine: An allograft bone block is commonly used in spinal fusion procedures. In this application, a surgeon places the graft between two or more vertebrae to fill the space that is created when a disc is removed. The allograft bone block allows for incorporation of the patient's own bone over time. The advantage of using a spine allograft is the lack of a second surgery site, which will reduce the time in the operating room and pain from a secondary surgical site.

RTI pioneered the shaping of tissue to specific sizes and configurations to make spine surgery more convenient for surgeons and to give patients more options. RTI offers sterile, biological solutions used primarily for cervical and lumbar spinal fusion surgeries.

Dental: Allograft paste is used in dental procedures as a bone void filler to augment dental, oral and cranio/maxillofacial defects.

Dental implants consist of soft tissue grafts and bone void fillers used in surgeries such as dental bone grafting procedures, sinus grafting or in conjunction with dental implant procedures, usually for patients requiring bony enhancement of the mandible and maxilla.

General Orthopedic/Bone Graft Substitutes:

Bone graft substitutes consist of all moldable and flowable bone pastes, as well as chips and cubes. These safe, high quality implants can be used to fill bone voids or for repairing fractures and skeletal defects.



General Orthopedic implants have been used successfully for decades for skeletal defects and fracture repair, trauma procedures, reconstructive orthopedic procedures and other orthopedic surgeries. With advances in tissue sterilization, many safe and high quality options are available for surgeons and patients.



Surgical Specialties: These implants are typically derived from human dermal collagen and used in surgeries such as hernia or other complex abdominal wall repair cases. Surgical specialty implants include safe, quality biologic implants for use in Urology, Gynecology, Breast Reconstruction, Ophthalmology and Ear Nose & Throat (ENT) surgeries.

Great strides have been made in allograft safety with the invention of tissue sterilization technologies, therefore the risk of disease transmission through allograft is significantly reduced.

BOARD OF DIRECTORS

Dean H. Bergy, Chairman
Julianne M. Bowler
Philip R. Chapman
Roy D. Crowninshield, Ph.D.
Peter F. Gearen, MD
Brian K. Hutchison
Gregory P. Rainey
Adrian J.R. Smith

CORPORATE MANAGEMENT

Brian K. Hutchison	President and Chief Executive Officer
Thomas F. Rose	Executive Vice President and Chief Operations Officer
Robert P. Jordheim	Executive Vice President and Chief Financial Officer
Roger W. Rose	Executive Vice President and Chief Commercial Officer
Caroline A. Hartill	Executive Vice President and Chief Scientific Officer
Robby Lane	Vice President and General Manager of German Operations
Rod Allen	Vice President and General Manager of Sports Medicine
Michael LaPrade	Vice President, Commercial Marketing and Distribution
Christie Blakely	Vice President, Customer Relations and Compliance
Beverly Bliss	Vice President, RTI Donor Services
Karen Norman	Vice President, Quality Assurance and Regulatory Affairs

CONTACT INFORMATION

Media contact:

Corporate Communications
Tel 386.418.8888

Investor contacts:

Robert P. Jordheim
Executive Vice President and Chief Financial Officer
rjordheim@rtix.com

Wendy Crites Wacker, APR
Director, Corporate Communications
wwacker@rtix.com

Corporate Headquarters

11621 Research Circle
Alachua, FL 32615
Tel 386.418.8888
Toll Free 877.343.6832
Fax 386.418.0342

www.rtix.com or
www.rtiblogics.com

RTI | BIOLOGICS®